Sensorium Therapeutics

Executive Summary

Sensorium Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel central nervous system (CNS) therapies derived from natural compounds with a history of human use. Leveraging its proprietary SensAI™ platform, the company systematically decodes natural motifs to create mechanistically driven, precise treatments for brain and mental health conditions. Its lead program, SENS-01, is currently in Phase 1 clinical trials for anxiety disorders. Founded in 2021 and headquartered in Boston, Sensorium operates at the intersection of psychedelic-inspired medicine and advanced AI-driven drug discovery, aiming to address the significant unmet need in psychiatric care with potentially safer and more effective therapies. Sensorium's approach offers a unique value proposition by combining ethnopharmacological insights with modern computational tools, potentially reducing development risks and timelines. The company is well-positioned to capitalize on the growing interest in psychedelic-based treatments, though it remains early in its clinical journey. Key near-term milestones include Phase 1 data for SENS-01, which will be critical for validating the platform and derisking subsequent trials. With a strong scientific foundation and a clear focus on CNS disorders, Sensorium represents a promising but speculative investment opportunity in the emerging psychedelics biotech space.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 top-line data for SENS-01 in anxiety disorders70% success
• Q4 2026Series A or B financing round60% success
• H1 2027Partnership or licensing deal for SensAI platform40% success